AUTX-703, a novel, oral KAT2A/B degrader, has received fast track designation for use in relapsed/refractory AML.
Experts discuss the role of supportive therapies, such as antiemetics, nutritional support, and physical activity, in improving outcomes and patient comfort during treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback